Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14895486 | 0.74 | PIK3CD (0.40) | DYRK1APIK3CDCHRM5ALDH1A1HSD17B10 | |
| SCHEMBL25209473 | 0.74 | ALDH1A1 (0.41) | PIK3CDALDH1A1HSD17B10TDP1PDE4B | |
| SCHEMBL14907579 | 0.71 | CHRM5 (0.33) | DYRK1APIK3CDCHRM5CYP3A4CYP2D6 | |
| SCHEMBL651902 | 0.68 | ALDH1A1 (0.71) | ALDH1A1HSD17B10TDP1CYP3A4CYP2C9 | |
| SCHEMBL16825381 | 0.68 | MEN1 (0.51) | DYRK1ANAMPTCYP2C9 | |
| SCHEMBL421292 | 0.67 | DYRK1A (0.47) | DYRK1APIK3CDSCN5ATGFBR1 | |
| SCHEMBL18077230 | 0.67 | SCN5A (0.47) | DYRK1APIK3CDSCN5ACHRM5TGFBR1 | |
| SCHEMBL3384490 | 0.67 | DYRK1A (0.56) | DYRK1APIK3CDSCN5ACHRM5TGFBR1 | |
| SCHEMBL1585961 | 0.67 | DYRK1A (0.47) | DYRK1APIK3CDNAMPTSCN5ACHRM5 | |
| SCHEMBL3326856 | 0.67 | DYRK1A (0.47) | DYRK1APIK3CDNAMPTSCN5ACHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771332-B1 | Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS | MERCK CANADA INC (CA) | 2016-06-29 | — | — | EP | disclosed |
| EP-2771332-B1 | Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS | MERCK CANADA INC (CA) | 2016-06-29 | — | — | EP | disclosed |
| US-9133157-B2 | HIV protease inhibitors | MERCK CANADA INC. (CA) | 2015-09-15 | — | — | US | disclosed |
| US-9133157-B2 | HIV protease inhibitors | MERCK CANADA INC. (CA) | 2015-09-15 | — | — | US | disclosed |
| US-20140303171-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2014-10-09 | — | — | US | disclosed |
| US-20140303171-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2014-10-09 | — | — | US | disclosed |
| EP-2771332-A1 | HIV PROTEASE INHIBITORS | Merck Canada Inc. (CA) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013059928-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013059928-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303171-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, PRSS3 | DYRK1A 4264/4885PIK3CD 2930/4885NAMPT 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.